Cargando…

Predictors of Pap smear testing uptake among women in Lagos, Nigeria

We assessed the predictors of Pap smear testing uptake within 6 months after cervical cancer prevention education among women in Lagos, Nigeria. This was a prospective follow-up study conducted as part of the ‘mHealth-Cervix trial’ in the two teaching hospitals in Lagos, Nigeria, between August 2020...

Descripción completa

Detalles Bibliográficos
Autores principales: Okunade, Kehinde S, John-Olabode, Sarah, Adejimi, Adebola A, Oshodi, Yusuf A, Osunwusi, Benedetto, Ugwu, Aloy O, Adefemi, Ayodeji, Anorlu, Rose I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9085162/
https://www.ncbi.nlm.nih.gov/pubmed/35685953
http://dx.doi.org/10.3332/ecancer.2022.1368
_version_ 1784703752689680384
author Okunade, Kehinde S
John-Olabode, Sarah
Adejimi, Adebola A
Oshodi, Yusuf A
Osunwusi, Benedetto
Ugwu, Aloy O
Adefemi, Ayodeji
Anorlu, Rose I
author_facet Okunade, Kehinde S
John-Olabode, Sarah
Adejimi, Adebola A
Oshodi, Yusuf A
Osunwusi, Benedetto
Ugwu, Aloy O
Adefemi, Ayodeji
Anorlu, Rose I
author_sort Okunade, Kehinde S
collection PubMed
description We assessed the predictors of Pap smear testing uptake within 6 months after cervical cancer prevention education among women in Lagos, Nigeria. This was a prospective follow-up study conducted as part of the ‘mHealth-Cervix trial’ in the two teaching hospitals in Lagos, Nigeria, between August 2020 and April 2021. Participants were followed up for 6 months after pre-enrolment cervical cancer prevention education. The potential socio-demographic and clinical predictors of Pap smear testing uptake during the 6-month follow-up were tested using the predictive model in a binary logistic regression analysis. Statistical significance was reported as p < 0.05. The rate of Pap smear testing uptake during the 6-month follow-up was 35.7%. Following the adjustments in the final multivariate analysis, participants’ previous awareness of Pap smearing (RR = 6.92, 95% CI: 8.37–56.68, p = 0.001) and attendance at the general outpatient clinic during the period of follow-up (RR = 11.22, 95% CI: 1.54–81.51, p = 0.017) independently predict Pap smear testing uptake. We will, therefore, explore the impact of continuous provision of health promotion on cervical cancer prevention and its effect in the context of routine clinical care in our next implementation research agenda. We recommend, in the meantime, that regular health education of women on cervical cancer prevention by healthcare providers should be further reinforced as an integral part of health promotion in clinics to reduce the burden of cervical cancer in most low- and middle-income settings.
format Online
Article
Text
id pubmed-9085162
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cancer Intelligence
record_format MEDLINE/PubMed
spelling pubmed-90851622022-06-08 Predictors of Pap smear testing uptake among women in Lagos, Nigeria Okunade, Kehinde S John-Olabode, Sarah Adejimi, Adebola A Oshodi, Yusuf A Osunwusi, Benedetto Ugwu, Aloy O Adefemi, Ayodeji Anorlu, Rose I Ecancermedicalscience Research We assessed the predictors of Pap smear testing uptake within 6 months after cervical cancer prevention education among women in Lagos, Nigeria. This was a prospective follow-up study conducted as part of the ‘mHealth-Cervix trial’ in the two teaching hospitals in Lagos, Nigeria, between August 2020 and April 2021. Participants were followed up for 6 months after pre-enrolment cervical cancer prevention education. The potential socio-demographic and clinical predictors of Pap smear testing uptake during the 6-month follow-up were tested using the predictive model in a binary logistic regression analysis. Statistical significance was reported as p < 0.05. The rate of Pap smear testing uptake during the 6-month follow-up was 35.7%. Following the adjustments in the final multivariate analysis, participants’ previous awareness of Pap smearing (RR = 6.92, 95% CI: 8.37–56.68, p = 0.001) and attendance at the general outpatient clinic during the period of follow-up (RR = 11.22, 95% CI: 1.54–81.51, p = 0.017) independently predict Pap smear testing uptake. We will, therefore, explore the impact of continuous provision of health promotion on cervical cancer prevention and its effect in the context of routine clinical care in our next implementation research agenda. We recommend, in the meantime, that regular health education of women on cervical cancer prevention by healthcare providers should be further reinforced as an integral part of health promotion in clinics to reduce the burden of cervical cancer in most low- and middle-income settings. Cancer Intelligence 2022-03-31 /pmc/articles/PMC9085162/ /pubmed/35685953 http://dx.doi.org/10.3332/ecancer.2022.1368 Text en © the authors; licensee ecancermedicalscience. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Okunade, Kehinde S
John-Olabode, Sarah
Adejimi, Adebola A
Oshodi, Yusuf A
Osunwusi, Benedetto
Ugwu, Aloy O
Adefemi, Ayodeji
Anorlu, Rose I
Predictors of Pap smear testing uptake among women in Lagos, Nigeria
title Predictors of Pap smear testing uptake among women in Lagos, Nigeria
title_full Predictors of Pap smear testing uptake among women in Lagos, Nigeria
title_fullStr Predictors of Pap smear testing uptake among women in Lagos, Nigeria
title_full_unstemmed Predictors of Pap smear testing uptake among women in Lagos, Nigeria
title_short Predictors of Pap smear testing uptake among women in Lagos, Nigeria
title_sort predictors of pap smear testing uptake among women in lagos, nigeria
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9085162/
https://www.ncbi.nlm.nih.gov/pubmed/35685953
http://dx.doi.org/10.3332/ecancer.2022.1368
work_keys_str_mv AT okunadekehindes predictorsofpapsmeartestinguptakeamongwomeninlagosnigeria
AT johnolabodesarah predictorsofpapsmeartestinguptakeamongwomeninlagosnigeria
AT adejimiadebolaa predictorsofpapsmeartestinguptakeamongwomeninlagosnigeria
AT oshodiyusufa predictorsofpapsmeartestinguptakeamongwomeninlagosnigeria
AT osunwusibenedetto predictorsofpapsmeartestinguptakeamongwomeninlagosnigeria
AT ugwualoyo predictorsofpapsmeartestinguptakeamongwomeninlagosnigeria
AT adefemiayodeji predictorsofpapsmeartestinguptakeamongwomeninlagosnigeria
AT anorlurosei predictorsofpapsmeartestinguptakeamongwomeninlagosnigeria